{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:51:31Z","timestamp":1780548691130,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Tianjin Health Research Project","award":["No. TJWJ2024QN007"],"award-info":[{"award-number":["No. TJWJ2024QN007"]}]},{"name":"Major Research Plan of National Natural Science Foundation of China","award":["No.92163213"],"award-info":[{"award-number":["No.92163213"]}]},{"name":"National Key Research and Development Program of China","award":["No. 2023YFC3605200"],"award-info":[{"award-number":["No. 2023YFC3605200"]}]},{"DOI":"10.13039\/501100019065","name":"Tianjin science and technology plan project","doi-asserted-by":"crossref","award":["No. 21JCZDJC00940"],"award-info":[{"award-number":["No. 21JCZDJC00940"]}],"id":[{"id":"10.13039\/501100019065","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Tianjin health science and technology projects","award":["No. TJWJ2022XK001"],"award-info":[{"award-number":["No. TJWJ2022XK001"]}]},{"name":"Tianjin Key Medical Discipline (Specialty) Construction Project","award":["No.TJYXZDXK-006A"],"award-info":[{"award-number":["No.TJYXZDXK-006A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-025-02538-1","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T08:00:51Z","timestamp":1746691251000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Combined effect of fasting blood glucose and serum uric acid on nonalcoholic fatty liver disease"],"prefix":"10.1186","volume":"24","author":[{"given":"Yifan","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuerui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"issue":"4","key":"2538_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology (Baltimore MD). 2023;77(4):1335\u201347.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"1","key":"2538_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore MD). 2016;64(1):73\u201384.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"4","key":"2538_CR3","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/hep.30702","volume":"70","author":"F Zhou","year":"2019","unstructured":"Zhou F, Zhou J, Wang W, Zhang XJ, Ji YX, Zhang P, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and Meta-Analysis. Hepatology (Baltimore MD). 2019;70(4):1119\u201333.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"1 Suppl","key":"2538_CR4","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47\u201364.","journal-title":"J Hepatol"},{"key":"2538_CR5","doi-asserted-by":"crossref","unstructured":"Guo X, Yin X, Liu Z, Wang J. Non-Alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment. Int J Mol Sci. 2022;23(24):15489.","DOI":"10.3390\/ijms232415489"},{"key":"2538_CR6","doi-asserted-by":"publisher","first-page":"3920196","DOI":"10.1155\/2020\/3920196","volume":"2020","author":"DM Tanase","year":"2020","unstructured":"Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res. 2020;2020:3920196.","journal-title":"J Diabetes Res"},{"issue":"3","key":"2538_CR7","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/JCI134165","volume":"130","author":"GI Smith","year":"2020","unstructured":"Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, Beals JW, et al. Insulin resistance drives hepatic de Novo lipogenesis in nonalcoholic fatty liver disease. J Clin Investig. 2020;130(3):1453\u201360.","journal-title":"J Clin Investig"},{"issue":"1","key":"2538_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12944-020-01326-3","volume":"19","author":"Y Zou","year":"2020","unstructured":"Zou Y, Yu M, Sheng G. Association between fasting plasma glucose and nonalcoholic fatty liver disease in a Nonobese Chinese population with normal blood lipid levels: a prospective cohort study. Lipids Health Dis. 2020;19(1):145.","journal-title":"Lipids Health Dis"},{"issue":"34","key":"2538_CR9","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.3346\/jkms.2023.38.e267","volume":"38","author":"JM Lee","year":"2023","unstructured":"Lee JM, Kim HW, Heo SY, Do KY, Lee JD, Han SK, et al. Associations of serum uric acid level with liver enzymes, nonalcoholic fatty liver disease, and liver fibrosis in Korean men and women: A Cross-Sectional study using nationally representative data. J Korean Med Sci. 2023;38(34):e267.","journal-title":"J Korean Med Sci"},{"issue":"7","key":"2538_CR10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.arcmed.2021.04.005","volume":"52","author":"P Toledo-Ibelles","year":"2021","unstructured":"Toledo-Ibelles P, Guti\u00e9rrez-Vidal R, Calixto-Tlacomulco S, Delgado-Coello B, Mas-Oliva J. Hepatic accumulation of hypoxanthine: A link between hyperuricemia and nonalcoholic fatty liver disease. Arch Med Res. 2021;52(7):692\u2013702.","journal-title":"Arch Med Res"},{"issue":"1","key":"2538_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12967-020-02296-x","volume":"18","author":"Z Ma","year":"2020","unstructured":"Ma Z, Xu C, Kang X, Zhang S, Li H, Tao L, et al. Changing trajectories of serum uric acid and risk of non-alcoholic fatty liver disease: a prospective cohort study. J Translational Med. 2020;18(1):133.","journal-title":"J Translational Med"},{"issue":"11","key":"2538_CR12","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1210\/jc.2015-2527","volume":"100","author":"H Yuan","year":"2015","unstructured":"Yuan H, Yu C, Li X, Sun L, Zhu X, Zhao C, et al. Serum uric acid levels and risk of metabolic syndrome: A Dose-Response Meta-Analysis of prospective studies. J Clin Endocrinol Metab. 2015;100(11):4198\u2013207.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2538_CR13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2174\/1570161115666170621082237","volume":"16","author":"P Paschos","year":"2018","unstructured":"Paschos P, Athyros VG, Tsimperidis A, Katsoula A, Grammatikos N, Giouleme O. Can serum uric acid Lowering therapy contribute to the prevention or treatment of nonalcoholic fatty liver disease?? Curr Vasc Pharmacol. 2018;16(3):269\u201375.","journal-title":"Curr Vasc Pharmacol"},{"issue":"3","key":"2538_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1517\/14728222.2016.1096930","volume":"20","author":"DQ Sun","year":"2016","unstructured":"Sun DQ, Wu SJ, Liu WY, Lu QD, Zhu GQ, Shi KQ, et al. Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease. Expert Opin Ther Targets. 2016;20(3):375\u201387.","journal-title":"Expert Opin Ther Targets"},{"issue":"33","key":"2538_CR15","doi-asserted-by":"publisher","first-page":"e26946","DOI":"10.1097\/MD.0000000000026946","volume":"100","author":"H Yu","year":"2021","unstructured":"Yu H, Zhao L, Liu L, Li Y, Sun J, Liu Y. Relationship between serum uric acid level and nonalcoholic fatty liver disease in type 2 diabetes patients. Medicine. 2021;100(33):e26946.","journal-title":"Medicine"},{"key":"2538_CR16","doi-asserted-by":"publisher","first-page":"e7563","DOI":"10.7717\/peerj.7563","volume":"7","author":"L Xu","year":"2019","unstructured":"Xu L, Li T, Yin J, Lin G, Xu Y, Ren Y, et al. Association between serum uric acid and nonalcoholic fatty liver disease in community patients with type 2 diabetes mellitus. Peer J. 2019;7:e7563.","journal-title":"PeerJ"},{"key":"2538_CR17","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee. WHO Guidelines on Physical Activity and Sedentary Behaviour. Geneva: World Health Organization \u00a9 World Health Organization 2020.; 2020."},{"issue":"5","key":"2538_CR18","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00535-012-0533-z","volume":"47","author":"Y Eguchi","year":"2012","unstructured":"Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47(5):586\u201395.","journal-title":"J Gastroenterol"},{"issue":"6","key":"2538_CR19","doi-asserted-by":"publisher","first-page":"e2301","DOI":"10.1210\/clinem\/dgac122","volume":"107","author":"H Zhou","year":"2022","unstructured":"Zhou H, Zeng X, Xue Y, Wang X, Liu S, Zhu Z, et al. Visit-to-Visit fasting glucose variability in young adulthood and nonalcoholic fatty liver disease in middle age. J Clin Endocrinol Metab. 2022;107(6):e2301\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2538_CR20","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1002\/hep.30083","volume":"68","author":"Y Pang","year":"2018","unstructured":"Pang Y, Kartsonaki C, Turnbull I, Guo Y, Clarke R, Chen Y, et al. Diabetes, plasma glucose, and incidence of fatty liver, cirrhosis, and liver cancer: A prospective study of 0.5 million people. Hepatology (Baltimore MD). 2018;68(4):1308\u201318.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"2","key":"2538_CR21","first-page":"136","volume":"49","author":"G Darmawan","year":"2017","unstructured":"Darmawan G, Hamijoyo L, Hasan I. Association between serum uric acid and Non-Alcoholic fatty liver disease: A Meta-Analysis. Acta Med Indones. 2017;49(2):136\u201347.","journal-title":"Acta Med Indones"},{"key":"2538_CR22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2147\/CLEP.S403314","volume":"15","author":"Q Sun","year":"2023","unstructured":"Sun Q, Zhang T, Manji L, Liu Y, Chang Q, Zhao Y, et al. Association between serum uric acid and Non-Alcoholic fatty liver disease: an updated systematic review and Meta-Analysis. Clin Epidemiol. 2023;15:683\u201393.","journal-title":"Clin Epidemiol"},{"issue":"1","key":"2538_CR23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12944-017-0531-5","volume":"16","author":"X Zheng","year":"2017","unstructured":"Zheng X, Gong L, Luo R, Chen H, Peng B, Ren W, et al. Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults. Lipids Health Dis. 2017;16(1):202.","journal-title":"Lipids Health Dis"},{"key":"2538_CR24","doi-asserted-by":"publisher","first-page":"1424207","DOI":"10.3389\/fendo.2024.1424207","volume":"15","author":"S Song","year":"2024","unstructured":"Song S, Cai X, Hu J, Zhu Q, Shen D, Ma H, et al. Plasma aldosterone concentrations elevation in hypertensive patients: the dual impact on hyperuricemia and gout. Front Endocrinol. 2024;15:1424207.","journal-title":"Front Endocrinol"},{"key":"2538_CR25","doi-asserted-by":"crossref","unstructured":"Hu J, Cai X, Zhu Q, Heizhati M, Wen W, Luo Q et al. Relationship between plasma aldosterone concentrations and Non-Alcoholic fatty liver disease diagnosis in patients with hypertension: A retrospective cohort study. Diabetes, metabolic syndrome and obesity: targets and therapy. 2023;16:1625\u201336.","DOI":"10.2147\/DMSO.S408722"},{"key":"2538_CR26","doi-asserted-by":"publisher","first-page":"1451383","DOI":"10.3389\/fendo.2024.1451383","volume":"15","author":"D Shen","year":"2024","unstructured":"Shen D, Cai X, Hu J, Song S, Zhu Q, Ma H, et al. Associating plasma aldosterone concentration with the prevalence of MAFLD in hypertensive patients: insights from a large-scale cross-sectional study. Front Endocrinol. 2024;15:1451383.","journal-title":"Front Endocrinol"},{"key":"2538_CR27","doi-asserted-by":"publisher","first-page":"e10691","DOI":"10.7717\/peerj.10691","volume":"9","author":"Y Hu","year":"2021","unstructured":"Hu Y, Li Q, Min R, Deng Y, Xu Y, Gao L. The association between serum uric acid and diabetic complications in patients with type 2 diabetes mellitus by gender: a cross-sectional study. Peer J. 2021;9:e10691.","journal-title":"PeerJ"},{"issue":"5","key":"2538_CR28","doi-asserted-by":"publisher","first-page":"107874","DOI":"10.1016\/j.jdiacomp.2021.107874","volume":"35","author":"Y Cui","year":"2021","unstructured":"Cui Y, Liu J, Shi H, Hu W, Song L, Zhao Q. Serum uric acid is positively associated with the prevalence of nonalcoholic fatty liver in non-obese type 2 diabetes patients in a Chinese population. J Diabetes Complicat. 2021;35(5):107874.","journal-title":"J Diabetes Complicat"},{"issue":"2","key":"2538_CR29","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s11154-023-09787-4","volume":"24","author":"W Yu","year":"2023","unstructured":"Yu W, Xie D, Yamamoto T, Koyama H, Cheng J. Mechanistic insights of soluble uric acid-induced insulin resistance: insulin signaling and beyond. Reviews Endocr Metabolic Disorders. 2023;24(2):327\u201343.","journal-title":"Reviews Endocr Metabolic Disorders"},{"issue":"4","key":"2538_CR30","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.jhep.2015.11.022","volume":"64","author":"X Wan","year":"2016","unstructured":"Wan X, Xu C, Lin Y, Lu C, Li D, Sang J, et al. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. J Hepatol. 2016;64(4):925\u201332.","journal-title":"J Hepatol"},{"issue":"11","key":"2538_CR31","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1111\/liv.13185","volume":"36","author":"L Valenti","year":"2016","unstructured":"Valenti L, Bugianesi E, Pajvani U, Targher G. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? Liver International: Official J Int Association Study Liver. 2016;36(11):1563\u201379.","journal-title":"Liver International: Official J Int Association Study Liver"},{"issue":"4","key":"2538_CR32","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3390\/ijms17040548","volume":"17","author":"R Lombardi","year":"2016","unstructured":"Lombardi R, Pisano G, Fargion S. Role of serum uric acid and ferritin in the development and progression of NAFLD. Int J Mol Sci. 2016;17(4):548.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2538_CR33","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/hep4.1822","volume":"6","author":"F Luo","year":"2022","unstructured":"Luo F, Oldoni F, Das A. TM6SF2: A novel genetic player in nonalcoholic fatty liver and cardiovascular disease. Hepatol Commun. 2022;6(3):448\u201360.","journal-title":"Hepatol Commun"},{"issue":"3","key":"2538_CR34","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jcmgh.2021.12.008","volume":"13","author":"F Luo","year":"2022","unstructured":"Luo F, Smagris E, Martin SA, Vale G, McDonald JG, Fletcher JA, et al. Hepatic TM6SF2 is required for lipidation of VLDL in a Pre-Golgi compartment in mice and rats. Cell Mol Gastroenterol Hepatol. 2022;13(3):879\u201399.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"6","key":"2538_CR35","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1194\/jlr.M075028","volume":"58","author":"G Musso","year":"2017","unstructured":"Musso G, Cipolla U, Cassader M, Pinach S, Saba F, De Michieli F, et al. TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD. J Lipid Res. 2017;58(6):1221\u20139.","journal-title":"J Lipid Res"},{"issue":"5","key":"2538_CR36","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(5):1264\u2013e814.","journal-title":"Gastroenterology"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02538-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-025-02538-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02538-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T20:02:50Z","timestamp":1746734570000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-025-02538-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2538"],"URL":"https:\/\/doi.org\/10.1186\/s12944-025-02538-1","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the Ethics Committee of Tianjin Medical University General Hospital (Ethical No. IRB2022-YX-135-01). All participants signed written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"168"}}